相似文献
1
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
Nanomedicine (Lond). 2009 Dec;4(8):903-17. doi: 10.2217/nnm.09.71.
2
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
Int J Nanomedicine. 2011;6:3393-404. doi: 10.2147/IJN.S27830. Epub 2011 Dec 20.
3
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
J Control Release. 2011 Mar 10;150(2):204-11. doi: 10.1016/j.jconrel.2010.11.019. Epub 2010 Nov 23.
4
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
J Neuroimmune Pharmacol. 2010 Dec;5(4):592-601. doi: 10.1007/s11481-010-9198-7. Epub 2010 Mar 17.
5
Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.
Nanotoxicology. 2011 Dec;5(4):592-605. doi: 10.3109/17435390.2010.541292. Epub 2010 Dec 22.
6
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Int J Nanomedicine. 2012;7:2373-88. doi: 10.2147/IJN.S29454. Epub 2012 May 8.
7
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Nanomedicine. 2013 Nov;9(8):1263-73. doi: 10.1016/j.nano.2013.05.003. Epub 2013 May 13.
8
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Antimicrob Agents Chemother. 2013 Jul;57(7):3110-20. doi: 10.1128/AAC.00267-13. Epub 2013 Apr 22.
9
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Br J Clin Pharmacol. 2005 Sep;60(3):276-86. doi: 10.1111/j.1365-2125.2005.02436.x.
10
Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
Pathol Biol (Paris). 2002 Nov;50(9):565-7. doi: 10.1016/s0369-8114(02)00342-5.
引用本文的文献
1
The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential.
Int J Mol Sci. 2024 Dec 7;25(23):13167. doi: 10.3390/ijms252313167.
2
Macrophage based drug delivery: Key challenges and strategies.
Bioact Mater. 2024 Apr 23;38:55-72. doi: 10.1016/j.bioactmat.2024.04.004. eCollection 2024 Aug.
3
Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.
Pharmaceutics. 2024 Jan 28;16(2):183. doi: 10.3390/pharmaceutics16020183.
4
Lipid nanocarrier targeting activated macrophages for antiretroviral therapy of HIV reservoir.
Nanomedicine (Lond). 2023 Aug;18(20):1343-1360. doi: 10.2217/nnm-2023-0120. Epub 2023 Oct 10.
5
Prodrug approaches for the development of a long-acting drug delivery systems.
Adv Drug Deliv Rev. 2023 Jul;198:114860. doi: 10.1016/j.addr.2023.114860. Epub 2023 May 7.
6
Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.
Nanomedicine (Lond). 2022 Jun;17(13):959-978. doi: 10.2217/nnm-2022-0043. Epub 2022 Jun 1.
7
Virus-Mimicking Polymer Nanoparticles Targeting CD169 Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals.
ACS Appl Mater Interfaces. 2022 Jan 19;14(2):2488-2500. doi: 10.1021/acsami.1c17415. Epub 2022 Jan 7.
8
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
Nat Commun. 2021 Sep 16;12(1):5458. doi: 10.1038/s41467-021-25690-5.
9
Targeted and Non-Targeted Mechanisms for Killing Hypoxic Tumour Cells-Are There New Avenues for Treatment?
Int J Mol Sci. 2021 Aug 11;22(16):8651. doi: 10.3390/ijms22168651.
10
Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control.
Drug Deliv Transl Res. 2021 Aug;11(4):1420-1437. doi: 10.1007/s13346-021-00965-y. Epub 2021 Mar 21.
本文引用的文献
1
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.
Prog Polym Sci. 2007;32(8-9):1054-1082. doi: 10.1016/j.progpolymsci.2007.05.014.
2
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.
J Immunol. 2009 Jul 1;183(1):661-9. doi: 10.4049/jimmunol.0900274. Epub 2009 Jun 17.
3
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Eur J Pharm Biopharm. 2009 Aug;72(3):502-8. doi: 10.1016/j.ejpb.2009.03.006. Epub 2009 Mar 27.
4
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.
Antivir Ther. 2009;14(1):1-12.
5
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles.
PLoS One. 2009;4(2):e4343. doi: 10.1371/journal.pone.0004343. Epub 2009 Feb 2.
6
Risperidone long-acting injection: a review of its long term safety and efficacy.
Neuropsychiatr Dis Treat. 2008 Oct;4(5):919-27. doi: 10.2147/ndt.s3311.
7
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
Antiviral Res. 2009 May;82(2):A99-109. doi: 10.1016/j.antiviral.2008.12.013. Epub 2009 Jan 25.
8
CNS drug delivery systems: novel approaches.
Recent Pat Drug Deliv Formul. 2009 Jan;3(1):71-89. doi: 10.2174/187221109787158355.
9
Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles.
Biomacromolecules. 2009 Feb 9;10(2):408-16. doi: 10.1021/bm801178f.
10
Low atazanavir concentrations in cerebrospinal fluid.
AIDS. 2009 Jan 2;23(1):83-7. doi: 10.1097/QAD.0b013e328317a702.
Zotero 插件